Stay updated on Nivolumab for IDH Mutant Gliomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for IDH Mutant Gliomas Clinical Trial page.

Latest updates to the Nivolumab for IDH Mutant Gliomas Clinical Trial page
- Check6 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 in the header. No changes to study content or page layout were observed.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 was added; the government funding lapse notice and Revision: v3.4.1 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedAdded a government funding lapse notice at the top of the page and updated the page revision tag from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedThe page adds UI/metadata elements (Show glossary; Results First Posted and Last Update Posted timestamps; Revision: v3.4.0) and removes older labels (Revision: v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check84 days agoChange DetectedThe page now includes a consolidated Locations section listing Florida, Massachusetts, and New York sites, replacing the previous separate location pages for these sites.SummaryDifference0.4%

- Check91 days agoChange DetectedA new citation is added in Publications: Snyder et al., 2014 NEJM on CTLA-4 blockade in melanoma. The Erratum reference for that paper is removed.SummaryDifference0.1%

Stay in the know with updates to Nivolumab for IDH Mutant Gliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for IDH Mutant Gliomas Clinical Trial page.